Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperuricemia is frequently observed in CKD patients. The optimal dosing strategy for urate-lowering therapy in chronic kidney disease (CKD) to balance efficacy and renoprotection is not well-defined. This study compares the effects of continuous versus intermittent febuxostat dosing on serum uric acid (SUA) and renal function.
This prospective longitudinal cohort study was conducted from January 2024 to December 2024 at Khwaja Yunus Ali Medical College Hospital, a tertiary hospital located in a rural area of Bangladesh. Participants were enrolled at different time points, and each was followed for six months. We selected 60 CKD (Stage III–IV) patients with hyperuricemia, irrespective of age and sex. Among these patients, 29 (Group A) received continuous febuxostat 40 mg daily, and 31 (Group B) received an intermittent regimen of febuxostat 40 mg (20 days per month). Renal function and serum uric acid levels were assessed at baseline, 1 month, and 6 months. Linear mixed-effects models were fitted to evaluate the fixed effects of Group, Time, and their interaction on eGFR and serum uric acid (SUA), with a random intercept for subject ID to account for repeated measures.
The overall Group*Time interaction for eGFR was not statistically significant (F=1.42, p=0.245). However, post-hoc simple effects analysis revealed distinct patterns within each group. In Group A (continuous dosing), eGFR increased from baseline to Month 1 (+3.90 mL/min/1.73m², p<0.001), which was highly statistically significant. After 6 months, the improvement was smaller (+1.34 mL/min/1.73m², p=0.028), showing marginal significance. In Group B (intermittent dosing), eGFR also showed an initially highly statistically significant improvement at Month 1 (+2.87 mL/min/1.73m², p<0.001), which was better maintained and showed a significant net improvement at Month 6 (+1.68 mL/min/1.73m², p=0.005). A strong Group*Time interaction was found for SUA (F=26.8, p<0.001). Both groups showed a significant reduction in SUA from baseline after one month. However, at Month 6, Group A SUA levels fell further to 173 µmol/L, while Group B showed sustained levels at 289 µmol/L. The interaction term (B-A)*(Month6-Baseline) was highly significant (Estimate=109.01, p<0.001). Post-hoc analysis of simple effects confirmed that both groups achieved significant reductions from baseline at both Month 1 and Month 6 (all p < 0.001).
Intermittent febuxostat dosing achieves stable and moderate uric acid control, which is associated with a sustained, significant improvement in renal function. In contrast, continuous dosing leads to profound urate suppression but only a transient and marginal renal benefit. These findings suggest that intermittent dosing of febuxostat may be preferable for renoprotection in advanced CKD with hyperuricemia. However, these results require confirmation in larger, long-term studies.
